A股異動 | 貝達藥業(300558.SZ)大漲10% 擬推2021年限制性股票激勵計劃
格隆匯9月3日丨貝達藥業(300558.SZ)大幅拉昇漲10%,報80.45元,大幅成交5億元為昨日全天成交額2倍,總市值333億元。貝達藥業公佈2021年限制性股票激勵計劃(草案),該計劃擬向激勵對象授予的第二類限制性股票總量為1555萬股,約佔公吿時公司股本總額的3.7442%。激勵計劃首次授予激勵對象限制性股票的授予價格為41.34元/股,首次激勵對象總人數為468人。機構普遍認為公司股權激勵目標積極。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.